drugset / Trial / NCT02173652

Pharmacokinetics and Pharmacodynamics of Multiple 5 mg Doses of BI 1356 p.o. Given Once Daily Compared to Multiple 2.5 mg Doses Given Twice Daily in Healthy Male and Female Volunteers

NCT02173652

Phase 1 Completed 16 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

The objective was to investigate the influence of 2 different dosage regimens (5 mg once daily vs. 2.5 mg twice daily) on the steady-state pharmacokinetics and pharmacodynamics of orally administered BI 1356.

Timeline

Start
2008-03
Primary completion
2008-04
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Linagliptin Small molecule 2.5 mg Oral
Comparator Linagliptin Small molecule 5 mg Oral

Indications

No indication recorded.